.jpg)
The lung cancer study which is led by the University of Birmingham’s Cancer Research UK Clinical Trials Unit, and has been published in Nature, highlights the importance of the new approaches needed when treating genomically complicated cancers.
The National Lung Matrix Trial (NLMT) is the world’s largest precision medicine clinical trial for non-small-cell lung cancer (NSCLC) patients, it is funded by Cancer Research UK (CRUK) and supported by the charity’s Stratified Medicine Programme Phase 2 (SMP2) screening platform.
The trial matches different treatment options to different groups of patients and since opening to recruitment in 2015, 288 patients have been recruited to the 19 different treatment cohorts in the trial.
You can read more about the trial here